| 1. |
- Aad, G, et al.
(författare)
-
- 2015
-
swepub:Mat__t
|
|
| 2. |
- Fitzmauric, C., et al.
(författare)
-
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 : A Systematic Analysis for the Global Burden of Disease Study
- 2019
-
Ingår i: JAMA Oncology. - : American Medical Association. - 2374-2437 .- 2374-2445. ; 5:12, s. 1749-1768
-
Tidskriftsartikel (refereegranskat)abstract
- Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data.Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning.Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence.Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs).Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.
|
|
| 3. |
|
|
| 4. |
- Berglund, U. W., et al.
(författare)
-
Validation and development of MTH1 inhibitors for treatment of cancer
- 2016
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 27:12, s. 2275-2283
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Previously, we showed cancer cells rely on the MTH1 protein to prevent incorporation of otherwise deadly oxidised nucleotides into DNA and we developed MTH1 inhibitors which selectively kill cancer cells. Recently, several new and potent inhibitors of MTH1 were demonstrated to be non-toxic to cancer cells, challenging the utility of MTH1 inhibition as a target for cancer treatment. Material and methods: Human cancer cell lines were exposed in vitro to MTH1 inhibitors or depleted of MTH1 by siRNA or shRNA. 8-oxodG was measured by immunostaining and modified comet assay. Thermal Proteome profiling, proteomics, cellular thermal shift assays, kinase and CEREP panel were used for target engagement, mode of action and selectivity investigations of MTH1 inhibitors. Effect of MTH1 inhibition on tumour growth was explored in BRAF V600E-mutated malignant melanoma patient derived xenograft and human colon cancer SW480 and HCT116 xenograft models. Results: Here, we demonstrate that recently described MTH1 inhibitors, which fail to kill cancer cells, also fail to introduce the toxic oxidized nucleotides into DNA. We also describe a new MTH1 inhibitor TH1579, (Karonudib), an analogue of TH588, which is a potent, selective MTH1 inhibitor with good oral availability and demonstrates excellent pharmacokinetic and anti-cancer properties in vivo. Conclusion: We demonstrate that in order to kill cancer cells MTH1 inhibitors must also introduce oxidized nucleotides into DNA. Furthermore, we describe TH1579 as a best-in-class MTH1 inhibitor, which we expect to be useful in order to further validate the MTH1 inhibitor concept.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Jafari, F., et al.
(författare)
-
Notes on the genus Silene (Caryophyllaceae, Sileneae) in Iran
- 2019
-
Ingår i: Phytotaxa. - : Magnolia Press. - 1179-3155 .- 1179-3163. ; 425:1, s. 35-48
-
Tidskriftsartikel (refereegranskat)abstract
- Two new species-Silene orientoalborzensis and S. circumcarmanica-are here described from Northeast and South Iran, respectively. They belong to Silene subg. Silene sect. Auriculatae which is the largest section of the genus in W-Asia. A specimen from center of Iran, which was identified erroneously as S. atocioides, is revised and identified as S. pendula which represents a new record for the Iranian flora. S. simsii is proposed as a nomen novum for Cucubalus multifidus.
|
|
| 9. |
|
|
| 10. |
- Jafari, R., et al.
(författare)
-
KCI-induced corrosion behavior of HVAF-sprayed Ni-based coatings in ambient air
- 2017
-
Ingår i: Proceedings of the International Thermal Spray Conference & Exposition (ITSC 2017). - : Curran Associates, Inc.. - 9781510858220 ; , s. 946-950
-
Konferensbidrag (refereegranskat)abstract
- It is well known that the presence of KCl deposited on superheater tubes in biomass- and waste-fired boilers leads to a severe corrosion and premature damage. In order to protect such critical components which are routinely exposed to aggressive environments, thermal spray coatings are frequently proposed as a potential solution. By virtue of the techno-commercial benefits that provides as a direct outcome of its ability to cost-effectively deposit coatings virtually free of porosity and in situ formed oxides, the high velocity air-fuel (HVAF) process offers a particularly attractive approach. In the present work, the influence of KCl on the oxidation behavior of four HVAF-sprayed Ni-based coatings (Ni21Cr, Ni5AI, Ni21Cr7AI1Y, and Ni21Cr9Mo) has been investigated. The coatings were deposited onto specimens of 16Mo3 steel, a widely used boiler tube material. High temperature corrosion tests were carried out in ambient air at 600°C, with 0.1 mg/cm2 KCl being sprayed onto the samples prior to the exposure. Uncoated substrates and an identical test environment without KCl were used as reference. SEM/EDS and XRD techniques were utilized to characterize the as-sprayed and exposed samples. The results showed that the small addition of KCl significantly accelerated damage to the coatings. It was further revealed that the alumina-forming NiAl coating was capable of forming a more protective oxide scale compared to other chromia and mixed-oxide scale forming coatings. In general, the oxidation resistance of the coatings based on the kinetic studies had the following ranking (from the best to the worst): NiAl >NiCr> NiCrAlY> NiCrMo. © Copyright 2017 by DVS Media GmbH. All rights reserved.
|
|
